IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1101-1125 out of 1216.

<< < 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 > >>

Public Release: 19-Feb-2013
Journal of Neurosurgery
5-ALA fluorescence guides resection of recurrent glioblastoma multiforme
Neurosurgeons describe the use of 5-aminolevulinic acid (5-ALA) fluorescence in guiding resection of recurrent glioblastoma multiforme (GBM). Ingestion of 5-ALA by a patient before surgery leads to fluorescence of tumor cells intraoperatively in response to certain wavelengths of light. This can provide information not necessarily available through magnetic resonance imaging, the standard mode of imaging used to detect primary and recurrent GBMs, and can guide surgeons in the treatment of individual cases.

Contact: Jo Ann M Eliason
jaeliason@thejns.org
434-982-1209
Journal of Neurosurgery Publishing Group

Public Release: 19-Feb-2013
5th International Conference on Drug Discovery and Therapy
New compound holds high promise in battling kidney cancer
Chemists at the University of California, Riverside, have developed a compound that holds much promise in the laboratory in fighting renal (kidney) cancer. Named TIR-199, the compound targets the "proteasome," a cellular complex in kidney cancer cells, similar to the way the drug bortezomib, approved by the Food and Drug Administration, targets the proteasome in multiple myeloma cells, a cancer coming from bone marrow. The development of TIR-199 was announced Feb. 19, 2013, in Dubai.
University of California Institute for Mexico and the United States, UC Cancer Research Coordinating Committee

Contact: Iqbal Pittalwala
iqbal@ucr.edu
951-827-6050
University of California - Riverside

Public Release: 19-Feb-2013
Nature Immunology
Moffitt researchers say silencing of retinoblastoma gene regulates differentiation of myeloid cells
Researchers at the Moffitt Cancer Center have found a potential mechanism by which immune suppressive myeloid-derived suppressor cells can prevent immune response from developing in cancer. This mechanism includes silencing the tumor suppressor gene retinoblastoma 1 or Rb1. Their data explains a new regulatory mechanism by which myeloid-derived suppressor cells are expanded in cancer.

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 19-Feb-2013
Clinical Cancer Research
New drug combination could prevent head and neck cancer in high-risk patients
Preclinical combination of an EGFR inhibitor and a COX-2 inhibitor was effective. Advanced oral precancerous lesions were eliminated in three patients. Drug combination could be a new strategy to prevent head and neck cancers.

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research

Public Release: 19-Feb-2013
Epigenomics
BUSM authors propose potential epigenetic mechanisms for improved cancer therapy
A review article by researchers at Boston University School of Medicine proposes a new epigenetic hypothesis linked to tumor production and novel ideas about what causes progenitor cells to develop into cancer cells.
American Cancer Society

Contact: Jenny Eriksen Leary
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center

Public Release: 19-Feb-2013
Current Opinion in Gastroenterology
Study shows that diet of resistant starch helps the body resist colorectal cancer
A University of Colorado Cancer Center review published in this month's issue of the journal Current Opinion in Gastroenterology shows that resistant starch helps the body resist colorectal cancer through mechanisms including killing pre-cancerous cells and reducing inflammation that can otherwise promote cancer.
National Institutes of Health

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver

Public Release: 18-Feb-2013
Proceedings of the National Academy of Sciences
New study on Hepatitis C drug treatment in vivo and in vitro
An interdisciplinary effort by mathematical modelers, clinicians and virologists has revealed that daclatasvir has two main modes of action against HCV and also yields a more accurate new estimate of the HCV half-life.

Contact: Stasia Thompson
thoms@lumc.edu
708-417-5036
Loyola University Health System

Public Release: 18-Feb-2013
Annals of Internal Medicine
Annals of Internal Medicine tip sheet for Feb. 19, 2013
Below is information about articles being published in the Feb. 19 issue of Annals of Internal Medicine. The full TOC is also attached. The information is not intended to substitute for the full articles as a source of information. Annals of Internal Medicine attribution is required for all coverage.

Contact: Megan Hanks
mhanks@acponline.org
215-351-2656
American College of Physicians

Public Release: 18-Feb-2013
Food and Chemical Toxicology
Some cheeses exceed contaminant levels recommended by EU
Researchers at the University of Las Palmas de Gran Canaria (Spain) have analysed more than 60 brands of cheese commonly available in supermarkets. The concentration of organochloride contaminants in the majority of the samples was lower than levels set by European legislation, but in a few cases it was higher. The scientists recommend that an eye is kept on polychlorinated biphenyls as they are carcinogenic. The majority of these compound concentrations appeared in organic cheeses.

Contact: SINC
info@agenciasinc.es
34-914-251-820
FECYT - Spanish Foundation for Science and Technology

Public Release: 18-Feb-2013
PLOS Genetics
Pathway controlling cell growth revealed
A Melbourne-based research team has discovered a genetic defect that can halt cell growth and force cells into a death-evading survival state.
Australian National Health and Medical Research Council, Victorian Government, Ludwig Institute

Contact: Vanessa Solomon
solomon@wehi.edu.au
61-393-452-971
Walter and Eliza Hall Institute

Public Release: 18-Feb-2013
Proceedings of the National Academy of Sciences
Bone marrow cells used in bladder regeneration
A new approach to bladder regeneration uses bone marrow cells to recreate the organ's smooth muscle, vasculature and nerve tissue.
Illinois Department of Healthcare and Family Services

Contact: Marla Paul
marla-paul@northwestern.edu
312-503-8928
Northwestern University

Public Release: 18-Feb-2013
Proceedings of the National Academy of Sciences
In fight against cancer, a closer look at nuclear blebbing
Misshapen cell nuclei are frequently observed in the cells of people with cancer and other diseases, but what causes the abnormality -- and why it is associated with certain disorders -- has remained unclear. Northwestern University researchers have developed a mathematical model that clarifies the mechanisms that cause bulges known as "blebs" in cells' nuclear membranes. The work could be a step toward bleb prevention, which may ultimately provide potential therapies for related diseases.
US Department of Energy

Contact: Megan Fellman
fellman@northwestern.edu
847-491-3115
Northwestern University

Public Release: 18-Feb-2013
Journal of Experimental Medicine
Gene linked to worse outcomes for melanoma
Scientists at Queen Mary, University of London have identified a gene present in some melanoma which appears to make the tumour cells more resistant to treatment, according to research published today in the Journal of Experimental Medicine.
Medical Research Council, Cancer Research UK, Barts and The London Charity

Contact: Katrina Coutts
k.coutts@qmul.ac.uk
Queen Mary, University of London

Public Release: 18-Feb-2013
Journal of Medicinal Chemistry
Molecules generated that can halt metastasis of colon cancer
A Basque research consortium has managed to halt the progress of colon cancer and its metastasis in the liver in an experimental model with mice. This advance, that may open a new path for the future treatment of such pathologies, has been achieved by creating molecules which interfere with the adhesion of tumor cells to other cells of the organism.

Contact: Oihane Lakar Iraizoz
o.lakar@elhuyar.com
34-943-363-040
Elhuyar Fundazioa

Public Release: 18-Feb-2013
Nature Genetics
Researchers in Manchester find genetic key to preventing spine tumors
Genetic medicine experts from Manchester Biomedical Research Centre at Saint Mary's Hospital and The University of Manchester have identified a new gene responsible for causing an inherited form of tumor, known as spinal meningioma.
The Children's Tumor Foundation, Association for International Cancer Research

Contact: Alison Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester

Public Release: 17-Feb-2013
Nature
'Activating' RNA takes DNA on a loop through time and space
Long segments of RNA -- encoded in our DNA but not translated into protein -- are key to physically manipulating DNA in order to activate certain genes, say Wistar researchers. These non-coding RNA-activator molecules help create a loop of DNA to open up genes for transcription. They have a crucial role in turning genes on and off during early embryonic development, and have also been connected with genetic diseases, such as FG syndrome, and cancer.
National Institutes of Health

Contact: Greg Lester
glester@wistar.org
215-898-3934
The Wistar Institute

Public Release: 17-Feb-2013
2013 AAAS Annual Meeting
Modern alchemy, fusion energy and more from Princeton
A possible Higgs boson of cancer and steps to give natural biodiversity a fighting chance will be among the topics Princeton University researchers will discuss during the 2013 AAAS annual meeting. All information is embargoed until the beginning of the respective session.

Contact: Morgan Kelly
mgnkelly@princeton.edu
609-258-5729
Princeton University

Public Release: 16-Feb-2013
2013 AAAS Annual Meeting
Mussel-inspired 'glue' for surgical repair and cancer drug delivery
When it comes to sticking power under wet conditions, marine mussels are hard to beat. Northwestern University's Phillip Messersmith has created new materials that mimic mussel adhesive proteins for three medical applications: sealants for fetal membrane repair, self-setting antibacterial hydrogels, and polymers for cancer drug delivery and thermal destruction of cancer cells. All of his materials contain a synthetic form of the catecholic amino acid DOPA (dihydroxyphenylalanine), one of the keys to mussels' sticking power.

Contact: Megan Fellman
fellman@northwestern.edu
847-491-3115
Northwestern University

Public Release: 15-Feb-2013
Journal of Clinical Investigation
A smoking gun in lung cancer epigenetics
In this issue of the Journal of Clinical Investigation, David Schrump and colleagues at the National Cancer Institute in Bethesda, MD, measured miRNA expression in normal human lung cells exposed to cigarette smoke condensate and lung cancer cells derived from smokers and non-smokers.
NIH/National Cancer Institute, Steven J. Solarz Memorial Fund

Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation

Public Release: 15-Feb-2013
Journal of Clinical Investigation
JCI early table of contents for Feb. 15, 2013
This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published online, Feb. 15, 2013, in the JCI: A smoking gun in lung cancer epigenetics; Researchers identify a factor that may contribute to increased heart attack-related mortality in diabetics; and many more.

Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation

Public Release: 15-Feb-2013
2013 AAAS Annual Meeting
Not your conventional nucleic acids
Northwestern University's Chad Mirkin has invented and developed a powerful nanomaterial that could revolutionize biomedicine: spherical nucleic acids (SNAs). The novel arrangement of nucleic acids imparts interesting chemical and physical properties that are very different from conventional nucleic acids. Potential applications include using SNAs to carry nucleic acid-based therapeutics to the brain for the treatment of glioblastoma, the most aggressive form of brain cancer, as well as other neurological disorders such as Alzheimer's and Parkinson's diseases.
NIH/National Cancer Institute, Northwestern's Cancer Center for Nanotechnology Excellence

Contact: Megan Fellman
fellman@northwestern.edu
847-491-3115
Northwestern University

Public Release: 15-Feb-2013
Oncogene
Moffitt researchers find potential new therapeutic target for treating non-small cell lung cancer
Researchers at Moffitt Cancer Center have found a potential targeted therapy for patients with tobacco-associated non-small cell lung cancer. It is based on the newly identified oncogene IKBKE, which helps regulate immune response.
NIH/National Cancer Institute

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 15-Feb-2013
Journal of the National Cancer Institute
Breast cancer risk prediction model for African American women underestimates risk
A breast cancer risk prediction model developed for African Americans tends to underestimate risk in certain subgroups, according to a new study from the Slone Epidemiology Center at Boston University. The model predicted estrogen receptor (ER)-negative breast cancer, which is a more aggressive form of breast cancer that disproportionately affects African American women, more poorly than ER-positive breast cancer.
NIH/National Cancer Institute, Susan G. Komen for the Cure

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center

Public Release: 15-Feb-2013
Journal of Clinical Investigation
Scientists find promising new approach to preventing progression of breast cancer
Doctors currently struggle to determine whether a breast tumor is likely to shift into an aggressive, life-threatening mode -- an issue with profound implications for treatment. Now a group from The Scripps Research Institute has identified a mechanism through which mitochondria, the powerhouses of a cell, control tumor aggressiveness. Based on their findings, the team developed a simple treatment that inhibits cancer progression and prolongs life when tested in mice.
National Institutes of Health, Department of Defense, California Breast Cancer Research Program, Susan G. Komen Foundation. Las Patronas

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute

Public Release: 15-Feb-2013
Nutrition and Cancer
Researchers at St. Michael's Hospital test tool for screening cancer patients for malnutrition
Considering the many things a cancer patient has to think about, it's easy to understand why maintaining proper nutrition may not be top of mind.

Contact: Kate Taylor
TaylorKa@smh.ca
647-393-7527
St. Michael's Hospital

Showing releases 1101-1125 out of 1216.

<< < 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 > >>

  Search News Releases

     

 

 

EurekAlert!